Giuliana Grossi

The clinical trials that supported the FDA decision, SEQUOIA and ALPINE, evaluated the efficacy of zanubrutinib and findings paved the way to add the therapy as a treatment option.

The study population consists of patients who received 1-3 prior lines of therapy for relapsed and lenalidomide-refractory multiple myeloma.

DMARDs are the most commonly used treatment for patients with rheumatoid arthritis but have been linked with pneumonia and other pulmonary infections.

The monoclonal antibody serves as the first and only therapy for treating hemolysis in adults with cold agglutinin disease, an extremely rare condition.

“Repurposing approved drugs developed for other conditions presents an attractive strategy to identify new treatment options and expand access to potentially lifesaving care,” investigators wrote.

P38 mitogen-activated protein kinase (p38 MAPK) inhibitors have been a focal point for inflammatory diseases but the lack of efficacy in treating rheumatoid arthritis led to examination of the MK2 pathway.

Based on data from the systematic review, investigators urge for the prioritization of sleep as a core clinical target and further investigation across the stages of psychosis.

Dr. Neomi Shah explains why improving access to behavioral care for insomnia needs to be prioritized.

Single and dual-task conditions were implemented to determine the reliability of the 3MBWT alongside the Timed Up and Go test in assessing balance-related fibromyalgia symptoms.

The study evaluated how intranasal mometasone furoate affected sleep-disordered breathing symptoms and patient quality of life by comparing its efficacy to intranasal saline in the pediatric patients.

Those who were assigned female at birth, had worse physical health, and self-reported symptoms of anxiety, were vulnerable to poor sleep quality in all aspects.

Clinician awareness is imperative with this comorbidity because overestimated asthma severity often results in over-treatment, according to investigators.

The relationship between C-section and childhood asthma has been investigated before, however, previous results have yielded conflicting evidence.

With public health efforts and therapeutic advancements the prognosis for this rare condition has progressed, but longer life expectancy has highlighted a multitude of areas that need attention in this population.

Sleep and epilepsy have been described as "unfortunate bedfellows" due to the complex relationship, and yet caretakers report a lack of support managing these issues commonly experienced by children.

Based on the identified biomarkers, it was possible to distinguish patients with a good predictive value for pain, sleep, and anxiety.

The potential mediating role of inflammation at 9 years, measured by CRP and IL-6, was investigated in the relationship between sleep and ADHD.

New data support following existing guidelines for mechanical ventilation in pneumonia from SARS-CoV-2, as mortality rates are similar regardless of cause for pneumonia.

E-cigarettes are marketed as an alternative to tobacco, though discussion within the research community emphasizes the inconsistencies in evidence regarding health and addiction among users.

The primary outcome was the number of days alive and out of the hospital at 90 days after trial initiation.

The daytime-nighttime appliance named DNA, serves as a novel alternative to existing treatment options for mild-to-moderate obstructive sleep apnea.

Results indicated similar outcomes between those who underwent tonsillectomy and mUPPP, with minor differences favoring the tonsillectomy group.

Promising results from the IMerge phase 3 clinical trial met the primary and secondary endpoints in the investigation of imetelstat, a novel telomerase inhibitor developed for hematologic malignancies.

The targeted patient population included those with sickle cell disease or beta thalassemia who were considered at high risk for complications, or otherwise ineligible for standard myeloablative hematopoietic stem cell transplant.

"The challenge right now is that we have no therapies in the emergency department to treat acute pain, outside of pain medications and IV opioids," Dr. Claudia Morris says in an interview.

The motive of the study wasn't to implement hematopoietic stem cell transplantation (HSCT) programs worldwide, but as a contribution to comprehensive cancer control efforts.

According to Dr. Corinna Schultz, a key part of the conversation of sickle cell trait (SCT) is centered around reproductive choices for the patient in the future.

Dr. Adam Lamble recommends that pediatric patients with AML and TP53 status should now be considered for transplant in first remission, and novel interventions are warranted.

Dr. Molly Tokaz and Dr. Lisa Force discuss the extensive data they collected on the utilization of hematopoietic stem cell transplantation (HSCT) for patients with AML.

Almost 25 years later, Dr. Claudia Morris concluded 2022 by presenting phase 2 data at the 64th ASH Annual Meeting that demonstrated the therapy's benefit, and her original premise. Her team's phase 3 trial evaluating Arg is currently underway.